Cost evaluation of risperidone compared with olanzapine

Matthew J. Byerly, Mary Weber, Deean Brooks, Sara Beth Casey, Sheila Elliot, Jason Hawkins

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This study evaluated costs associated with risperidone and olanzapine treatment for schizophrenia. Data were collected from the Department of Veterans Affairs computerized database nine months before and nine months after patients began continuous treatment with risperidone (N=23) or olanzapine (N=47). Both agents were associated with significant reductions in psychiatric hospitalization costs. Median increases in antipsychotic costs were significantly higher for patients treated with olanzapine ($1,892) than for those treated with risperidone ($733). Mean dosages were 3.5 mg per day for the risperidone group and 18 mg per day for the olanzapine group. Although both treatments were associated with similar reductions in costs of psychiatric inpatient and outpatient care, it was significantly less expensive to prescribe risperidone than olanzapine.

Original languageEnglish (US)
Pages (from-to)742-744
Number of pages3
JournalPsychiatric Services
Volume54
Issue number5
DOIs
StatePublished - May 1 2003

Fingerprint

olanzapine
Risperidone
Costs and Cost Analysis
costs
evaluation
Psychiatry
outpatient care
schizophrenia
hospitalization
Veterans
Ambulatory Care
Group
Antipsychotic Agents
Inpatients
Schizophrenia
Hospitalization
Therapeutics
Databases

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Health Professions(all)

Cite this

Byerly, M. J., Weber, M., Brooks, D., Casey, S. B., Elliot, S., & Hawkins, J. (2003). Cost evaluation of risperidone compared with olanzapine. Psychiatric Services, 54(5), 742-744. https://doi.org/10.1176/appi.ps.54.5.742

Cost evaluation of risperidone compared with olanzapine. / Byerly, Matthew J.; Weber, Mary; Brooks, Deean; Casey, Sara Beth; Elliot, Sheila; Hawkins, Jason.

In: Psychiatric Services, Vol. 54, No. 5, 01.05.2003, p. 742-744.

Research output: Contribution to journalArticle

Byerly, MJ, Weber, M, Brooks, D, Casey, SB, Elliot, S & Hawkins, J 2003, 'Cost evaluation of risperidone compared with olanzapine', Psychiatric Services, vol. 54, no. 5, pp. 742-744. https://doi.org/10.1176/appi.ps.54.5.742
Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J. Cost evaluation of risperidone compared with olanzapine. Psychiatric Services. 2003 May 1;54(5):742-744. https://doi.org/10.1176/appi.ps.54.5.742
Byerly, Matthew J. ; Weber, Mary ; Brooks, Deean ; Casey, Sara Beth ; Elliot, Sheila ; Hawkins, Jason. / Cost evaluation of risperidone compared with olanzapine. In: Psychiatric Services. 2003 ; Vol. 54, No. 5. pp. 742-744.
@article{0e8c49d736134075b5d6ca28c34ac4ec,
title = "Cost evaluation of risperidone compared with olanzapine",
abstract = "This study evaluated costs associated with risperidone and olanzapine treatment for schizophrenia. Data were collected from the Department of Veterans Affairs computerized database nine months before and nine months after patients began continuous treatment with risperidone (N=23) or olanzapine (N=47). Both agents were associated with significant reductions in psychiatric hospitalization costs. Median increases in antipsychotic costs were significantly higher for patients treated with olanzapine ($1,892) than for those treated with risperidone ($733). Mean dosages were 3.5 mg per day for the risperidone group and 18 mg per day for the olanzapine group. Although both treatments were associated with similar reductions in costs of psychiatric inpatient and outpatient care, it was significantly less expensive to prescribe risperidone than olanzapine.",
author = "Byerly, {Matthew J.} and Mary Weber and Deean Brooks and Casey, {Sara Beth} and Sheila Elliot and Jason Hawkins",
year = "2003",
month = "5",
day = "1",
doi = "10.1176/appi.ps.54.5.742",
language = "English (US)",
volume = "54",
pages = "742--744",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "5",

}

TY - JOUR

T1 - Cost evaluation of risperidone compared with olanzapine

AU - Byerly, Matthew J.

AU - Weber, Mary

AU - Brooks, Deean

AU - Casey, Sara Beth

AU - Elliot, Sheila

AU - Hawkins, Jason

PY - 2003/5/1

Y1 - 2003/5/1

N2 - This study evaluated costs associated with risperidone and olanzapine treatment for schizophrenia. Data were collected from the Department of Veterans Affairs computerized database nine months before and nine months after patients began continuous treatment with risperidone (N=23) or olanzapine (N=47). Both agents were associated with significant reductions in psychiatric hospitalization costs. Median increases in antipsychotic costs were significantly higher for patients treated with olanzapine ($1,892) than for those treated with risperidone ($733). Mean dosages were 3.5 mg per day for the risperidone group and 18 mg per day for the olanzapine group. Although both treatments were associated with similar reductions in costs of psychiatric inpatient and outpatient care, it was significantly less expensive to prescribe risperidone than olanzapine.

AB - This study evaluated costs associated with risperidone and olanzapine treatment for schizophrenia. Data were collected from the Department of Veterans Affairs computerized database nine months before and nine months after patients began continuous treatment with risperidone (N=23) or olanzapine (N=47). Both agents were associated with significant reductions in psychiatric hospitalization costs. Median increases in antipsychotic costs were significantly higher for patients treated with olanzapine ($1,892) than for those treated with risperidone ($733). Mean dosages were 3.5 mg per day for the risperidone group and 18 mg per day for the olanzapine group. Although both treatments were associated with similar reductions in costs of psychiatric inpatient and outpatient care, it was significantly less expensive to prescribe risperidone than olanzapine.

UR - http://www.scopus.com/inward/record.url?scp=0038541852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038541852&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.54.5.742

DO - 10.1176/appi.ps.54.5.742

M3 - Article

VL - 54

SP - 742

EP - 744

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 5

ER -